-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FUjiU8liLdnO3PhafOz8cHwJRlSO6cNc+kOOHA2W2P5fHLMzrmvfS0kOsmzVaNZX m3ry+GH2y5uwdmzqveC4ow== 0000950123-09-056183.txt : 20091102 0000950123-09-056183.hdr.sgml : 20091102 20091102151021 ACCESSION NUMBER: 0000950123-09-056183 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20091102 DATE AS OF CHANGE: 20091102 EFFECTIVENESS DATE: 20091102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 000-24274 FILM NUMBER: 091150907 BUSINESS ADDRESS: STREET 1: 6455 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584526600 MAIL ADDRESS: STREET 1: 6455 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 DEFA14A 1 c91740defa14a.htm DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No.  )
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
o   Preliminary Proxy Statement
o   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o   Definitive Proxy Statement
þ   Definitive Additional Materials
o   Soliciting Material Pursuant to §240.14a-12
 
LA JOLLA PHARMACEUTICAL COMPANY
 
(Name of Registrant as Specified In Its Charter)
 
 
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ   No fee required.
o   Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  (1)   Title of each class of securities to which transaction applies:
 
     
Common Stock, par value $0.01
     
 
 
  (2)   Aggregate number of securities to which transaction applies:
 
     
     
 
 
  (3)   Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 
     
     
 
 
  (4)   Proposed maximum aggregate value of transaction:
 
     
     
 
 
  (5)   Total fee paid:
 
     
     
 
o   Fee paid previously with preliminary materials.
 
o   Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  (1)   Amount Previously Paid:
 
     
     
 
 
  (2)   Form, Schedule or Registration Statement No.:
 
     
     
 
 
  (3)   Filing Party:
 
     
     
 
 
  (4)   Date Filed:
 
     
     
 

 

On November 2, 2009, La Jolla Pharmaceutical Company issued the following press release:
FOR IMMEDIATE RELEASE
LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES THE ADJOURNMENT OF
SPECIAL MEETING OF STOCKHOLDERS
SAN DIEGO, NOVEMBER 2, 2009 — La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company”) today announced that its Special Meeting of Stockholders, which was convened on October 30, 2009, was adjourned to November 6, 2009 at 11:00 a.m., local time, at 4225 Executive Square, Suite 495, La Jolla, California. As described in the Proxy Statement distributed to stockholders on or about October 7, 2009, the stockholders of the Company are being asked to vote upon a proposal to approve the liquidation and dissolution of the Company pursuant to a plan of liquidation and dissolution. Approximately ninety-three percent (93%) of the Company’s stockholders failed to return their proxy cards or otherwise indicate their votes with respect to this proposal prior to the start of the stockholders meeting. To pass, this proposal must be approved by holders of at least a majority of the Company’s outstanding voting shares, and as a result, abstentions and broker non-votes have the same effect as votes against the proposal.
Stockholders who have not voted on the proposals described in the Proxy Statement are encouraged to do so promptly. For stockholders who have already voted on the proposals, no additional action is necessary if you do not wish to change your vote. Proxies may be submitted or revoked at any time prior to the reconvening of the adjourned meeting on November 6, 2009. For assistance in voting your shares, please contact MacKenzie Partners, Inc., at (800) 322-2885 or call collect at (212) 929-5500.
Stockholders are urged to read the Proxy Statement, which contains important information about the stockholders’ meeting and the proposals to be voted upon and it should be read carefully before any decision is made with respect to the matters to be voted upon.

 

2

-----END PRIVACY-ENHANCED MESSAGE-----